US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

VSTM

Verastem (VSTM)

Verastem Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/19	05 : 05	Business Wire	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer	NASDAQ:VSTM	Verastem Inc
2024/04/04	20 : 30	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
2024/03/18	20 : 00	Business Wire	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/03/15	05 : 05	Business Wire	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	NASDAQ:VSTM	Verastem Inc
2024/03/12	06 : 07	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:VSTM	Verastem Inc
2024/03/11	20 : 30	Business Wire	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs	NASDAQ:VSTM	Verastem Inc
2024/03/06	07 : 27	Business Wire	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/03/06	06 : 30	Business Wire	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024	NASDAQ:VSTM	Verastem Inc
2024/02/09	06 : 22	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:VSTM	Verastem Inc
2024/02/02	23 : 49	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VSTM	Verastem Inc
2024/01/30	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/29	21 : 00	Business Wire	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers	NASDAQ:VSTM	Verastem Inc
2024/01/19	21 : 54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/19	06 : 00	Business Wire	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)	NASDAQ:VSTM	Verastem Inc
2024/01/11	21 : 00	Business Wire	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:VSTM	Verastem Inc
2024/01/10	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2024/01/09	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/05	21 : 00	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
2023/12/29	06 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/22	06 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/21	06 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/21	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/20	06 : 01	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:VSTM	Verastem Inc
2023/12/18	21 : 00	Business Wire	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics	NASDAQ:VSTM	Verastem Inc
2023/12/13	21 : 00	Business Wire	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2023/12/09	06 : 10	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:VSTM	Verastem Inc
2023/11/21	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:VSTM	Verastem Inc
2023/11/13	21 : 00	Business Wire	New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach	NASDAQ:VSTM	Verastem Inc
2023/11/09	07 : 01	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:VSTM	Verastem Inc
2023/11/09	06 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VSTM	Verastem Inc

Showing the most relevant articles for your search:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 次へ >>

US Dollar vs Yen

JP Morgan Chase

Financial Select Sector

Gold vs US Dollar

BNP Paribas (QX)

Energy Select Sector SPDR

American Express

Health Care Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約